EPCAM and lung cancer: The primary factor contributing to this diminished sensitivity in lung cancer patient samples is likely due to the missing of EpCAM‐negative CTCs with mesenchymal characteristics, which are associated with the tumor's metastatic potential [38], shorter progression‐free survival [39], and poorer survival [40] in lung cancer [41, 42].